תבנית:תרופה/אופדיבו - Opdivo
| קבוצה פרמקולוגית (ATC4) | L01XC Monoclonal antibodies |
|---|---|
| מרכיב פעיל (ATC5) | Nivolumab 10MG/ML L01XC17 |
| צורת מתן | תוך-ורידי - I.V |
| צורת מינון | תרכיז להכנת תמיסה לאינפוזיה, CONCENTRATE FOR SOLUTION FOR INFUSION למניעת מינון יתר או הרעלה יש ליטול את התרופה בהתאם למינון המומלץ כפי שמופיע בעלון לצרכן |
| התוויה | Unresectable or Metastatic Melanoma:Opdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced(unresectable or metastatic) melanoma in adults.Adjuvant Treatment of Melanoma:Opdivo is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resectionMetastatic Non-Small Cell Lung Cancer:- Opdivo, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.- Opdivo is indicated for the treatment of patients with metastatic non small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.Renal Cell Carcinoma:Opdivo as a single agent is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy.Opdivo in combination with ipilimumab is indicated for the first line treatment of patients with intermediate or poor risk, advanced renal cell carcinoma (RCC).-OPDIVO, in combination with cabozantinib, is indicated for the first-line treatment of patients with advanced RCCClassical Hodgkin Lymphoma:Opdivo is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after:* autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or* 3 or more lines of systemic therapy that includes autologous HSCT.Squamous Cell Carcinoma of the Head and Neck:Opdivo is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient(dMMR) Metastatic Colorectal Cancer:Opdivo, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.Urothelial carcinoma:OPDIVO is indicated for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC.Opdivo (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:- have disease progression during or following platinum-containing chemotherapy- have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.- Hepatocellular Carcinoma:Opdivo, as a single agent or in combination with ipilimumab, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) Child-Pugh A who have been previously treated with sorafenib.Small Cell Lung Cancer (SCLC):Opdivo is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum based chemotherapy and at least one other line of therapy.Esophageal carcinoma:--OPDIVO is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).-OPDIVO is indicated for the treatment of patients with unresectable, advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapyMalignant Pleural MesotheliomaOPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of patients with unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma |
| תבנית:נתוני סל/תרופה/אופדיבו - Opdivo | |
| עלון לרופא והחמרות לעלון |
|
| ערכים בוויקירפואה | ערכים קשורים בוויקירפואה |
|---|---|
| אופדיבו במאגר משרד הבריאות |
| חיפוש מאמרים | - |
|---|---|
| מידע ברשת | - |
| שם יצרן | BRISTOL - MYERS SQUIBB HOLDINGS PHARMA, LTD, LIABILITY COMPANY, USA |
| שם בעל הרישום | BRISTOL - MYERS SQUIBB, ISRAEL |
| רישיון | תאריך הגשה: 10/2014. רישיון מתאריך: 03/2015 |
| תאריך עדכון אחרון | 15/07/15 |
דף זה נוצר על ידי בוט ומגדיר תבנית עם פרטי התרופה.
- דף התרופה: אופדיבו - Opdivo
- לדריסה ידנית של פרטי התרופה: ניתן לערוך את דף התרופה לעיל. לדוגמה החליפו את:
{{תרופה/אופדיבו - Opdivo}}
ב:
{{תרופה/אופדיבו - Opdivo
| שם הפרמטר=ערך חדש (דורס את הערך שהבוט הגדיר)
}}
